Hamstra says that shorter regimens of radiotherapy for men whose prostates remained in tact post-surgery proved to be noninferior when compared to longer regimens. He adds that these shorter regimens are more convenient for patients, as well as more cost effective.
Padmanee Sharma discusses the constantly shifting landscape of immune response and how it differs from patient to patient. Sharma says in order to best treat a patient with bladder cancer, oncologists have to consider that immune response in patients will never be the same day to day.
Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.
Sartor says the test would lay out molecular data regarding a patient's malignancy and allow community oncologists to determine what would be the best course of treatment. He added that the hope for this study is to replace the "trial and error" method of treatment with something more concrete.
Agarwal says patients whose penile cancer does not spread to their lymph nodes have a 95% chance of survival over the course of 5 years, while survival for those whose cancer spreads to their lymph nodes is significantly less.
Emberton says that in treatment of most solid tumor cancers, oncologists have moved from treating the whole organ to specifically targeting the tumor.
Saeed Rafii, MD, PhD, MRCP, discusses the phase Ib JAVELIN solid tumor trial. The trial looks at the anti-PD-L1 antibody avelumab in patients with locally advanced or metastatic breast cancer.
Patrick Johnston, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses a phase I study that incorporated belinostat with standard CHOP chemotherapy for patients with newly diagnosed peripheral T-cell lymphoma. Johnston says the goal of the trial was to discover the maximum tolerable dose. He said there were no additional significant toxicities in patients and the combination was well-tolerated.
Branagan said in his study, which gave patients with myeloma a high-dose flu vaccine followed by a booster dose 30 days later, 66% of patients saw total serum protection from the ailment. he said previous efforts to vaccinate patients with myeloma has resulted in a 20% total serum protection.
Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.
​Benjamin Smith, MD, discusses a recent study looking at local treatments in breast cancer and the complication burdens associated with them. Smith says that any complications arising in patients with breast cancer within 2 years are strongly associated with their treatments.
Shak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.
Twelves said historically, chemotherapy combinations have been created utilizing empirical evidence, which he says is not a sound rationale for the combinations. He adds that due to certain biological properties of eribulin mesylate, the treatment warrants further investigation as a combination therapy.
APOBEC3B was investigated in a retrospective study of a cohort available for analysis from a Dutch study. Results shows patients with high levels of APOBEC3B had much worse outcomes compared to those with low levels.
Debu Tripathy, MD, discusses the further investigation into immunotherapy's role in treating breast cancer.
Rex Chin-Wei Yung, MD, FCCP, discusses the value of teamwork in oncology, specifically lung cancer, and the importance of pulmonologists.
Betty Hamilton, MD, discusses TET2 mutations in molecular mutations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) on allogeneic hematopoietic cell transplant outcomes.
​Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Denise Yardley, MD, says one of the biggest challenges the malignancy poses is triple negative breast cancer's heterogeneity, resulting in medical professionals having to rely on clinical path features that do not provide enough preciseness in treatment.
Linda Vahdat, MD, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB.
Katherine Van Loon, MD, discusses identifying recurrences in gastrointestinal cancers at a point where patients can receive further therapy.
Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.
Michael Birrer, MD, PhD, discusses several international phase III trials showing bevacizumab significantly prolonging progression free survival in patients with ovarian cancer.
Yael Cohen, MD, discusses VB111, a highly targeted anti-angiogenic agent. The treatment is currently going through a phase III trial for treating glioblastoma, phase I trial for thyroid cancer and phase II trial for ovarian cancer.
Joanne Blum, MD, PhD, discusses the function of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer.
Sabine Siesling discusses breast conserving surgery versus mastectomy. Siesling says her and her team found that internationally, the survival rate of breast cancer patients is lower when a mastectomy is performed, as compared to breast conserving surgery.
​Andrew D. Seidman, MD, attending physician, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses the shift paradigm of breast cancer treatment and the development of targeted agents that disrupt certain pathways.
Eric P. Winer, MD, discusses the survival rates of women with early stage breast cancer who received bevacizumab and/or carboplatin.
Peter Beitsch, MD, breast surgeon, Medical City Dallas Hospital, discusses a triplet of chemotherapy, trastuzumab, and pertuzumab in the adjuvant and neoadjuvant settings.
​Amanda L. Kong, MD, MS, FACS, discusses breast cancer care at high volume hospitals versus low volume hospitals. Kong says the study is the first one that looks at processes as a bundle and takes into account socioeconomic statuses of patients.